Wegovy Pill vs Wegovy Injection

Wegovy pill vs injection at a glance

Novo Nordisk sells Wegovy as an injection and, since late 2025, as a tablet. The two share one prescribing information document, one boxed warning about thyroid C-cell tumors, and one list of contraindications. What differs is how each is taken, which uses FDA approved, how each is stored, and what each costs through NovoCare Pharmacy.

The table below lists the label facts side by side. Both columns describe the same FDA-approved drug, so this comparison is about form and logistics rather than approval status.

Same active ingredient, different approved uses

Both products contain semaglutide, a GLP-1 receptor agonist, and the label says concomitant use with other semaglutide products or any other GLP-1 receptor agonist is not recommended. The injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, to reduce excess body weight in adults and pediatric patients aged 12 and older with obesity and in adults with overweight and a weight-related condition, and to treat noncirrhotic MASH with moderate to advanced fibrosis in adults under accelerated approval.

The tablet's indications are narrower. It is approved for adults for cardiovascular risk reduction and for weight reduction and maintenance. There is no pediatric tablet indication and no MASH tablet indication in the current label. The label also says breastfeeding is not recommended during treatment with Wegovy tablets. A prescriber chooses the form partly on those label boundaries, not only on preference.

How the pill and the injection are dosed

The tablet is taken once daily in the morning on an empty stomach with up to four ounces of plain water, swallowed whole, followed by at least 30 minutes before food, other drinks, or other oral medicines. The label starts at 1.5 mg daily for days 1 through 30, then 4 mg for days 31 through 60, 9 mg for days 61 through 90, and 25 mg from day 91 onward. If a patient does not tolerate 25 mg, the label says to consider switching to the 1.7 mg weekly injection.

The injection is given once weekly on the same day, at any time, with or without meals, under the skin of the abdomen, thigh, or upper arm. It starts at 0.25 mg weekly for four weeks and escalates every four weeks toward a usual 2.4 mg maintenance dose, with a 7.2 mg Wegovy HD pen also listed. The label allows a switch from 2.4 mg weekly to the 25 mg tablet one week after the last injection, and a switch back from tablets to injection. Those switches are label instructions for a prescriber, not a self-serve option.

Dose changes and switches between the tablet and the injection belong to the prescriber. Do not split, crush, or chew tablets, and do not combine the two forms.

Storage and daily logistics

Tablets are stored at 68°F to 77°F in the original bottle to protect them from moisture, which makes travel simple. Single-dose pens and syringes are stored in the refrigerator at 36°F to 46°F and can be kept at up to 86°F for up to 28 days before the cap is removed. The four-dose FlexTouch pen is refrigerated before first use and then lasts 56 days at room temperature or in the refrigerator.

The daily routine is the real tradeoff. The tablet requires a fasting morning window every day. The injection requires cold storage, a needle, and one weekly step. The label's missed-dose rules differ by form, so anyone changing between them should read the current Medication Guide with the prescriber.

Where to buy each form

Both forms are prescription products filled at retail pharmacies or through NovoCare Pharmacy, Novo Nordisk's home-delivery channel with free shipping through its dispensing pharmacy, CoAssist Pharmacy. NovoCare's page says every dose of Wegovy requires a prescription and lists telehealth prescribers, home delivery, and pharmacy pickup as the three routes. A telehealth program that prescribes Wegovy is prescribing the same Novo Nordisk product in either form.

The pill has also changed the compounding conversation. Oral or sublingual semaglutide sold by some telehealth programs is compounded, not FDA-approved, and not the Wegovy tablet. FDA states that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, so an oral semaglutide listing needs to say plainly whether it is the Wegovy pill or a pharmacy product.

What each form costs through Novo Nordisk

NovoCare Pharmacy prices the pill by dose: $149 per month for 1.5 mg, $199 for 4 mg, and $299 for 9 mg and 25 mg, with a month defined as one bottle of 30 tablets. The pen costs $199 per month for the 0.25 mg and 0.5 mg doses for two monthly fills through December 31, 2026 for patients new to the program, then $349 per month for 0.25 mg through 2.4 mg and $399 per month for the 7.2 mg Wegovy HD pen, with a month defined as one box of four pens. Across a full maintenance year the tablet is the lower self-pay figure on Novo Nordisk's published page.

Commercially insured patients may pay as little as $25 per month for up to three months on either form, capped at $100 of savings per month, with government beneficiaries excluded. Eligible Medicare Part D beneficiaries pay $50 through the Medicare GLP-1 Bridge, which lists all Wegovy formulations through December 31, 2027. The catalog module below shows telehealth program prices for Wegovy and the Wegovy pill, which add clinician and membership fees on top of the medication.

What to ask a telehealth provider

These questions confirm which form you are getting and what the monthly total will be.

• Is this the FDA-approved Wegovy tablet or pen from Novo Nordisk, or a compounded oral or injectable semaglutide?
• Which pharmacy fills it, and is the medication price separate from the visit or membership fee?
• Does the program price match or exceed NovoCare's self-pay price for the same dose, and what does the extra pay for?
• How will dose escalation be handled month to month, and who reviews tolerability before each step?
• If I later switch between the tablet and the injection, who manages the switch?